Finasteride and flutamide therapy in patients with advanced prostate cancer: Response to subsequent castration and long-term follow-up

Urology

Volumn 62, Issue 1, 2003, Pages 99-104

  Oh, William K ^a   Manola, Judith ^b   Bittmann, Laurie ^b   Brufsky, Adam ^b   Kaplan, Irving D ^b   Smith, Matthew R ^b   Kaufman, Donald S ^b   Kantoff, Philip W ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; FLUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; AMNESIA; ANEMIA; ANTIGEN DETECTION; ANXIETY; ARTHRALGIA; ARTICLE; BONE PAIN; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; CASTRATION; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DYSPEPSIA; DYSURIA; FATIGUE; FECES INCONTINENCE; FLATULENCE; FOLLOW UP; GYNECOMASTIA; HEMATURIA; HOT FLUSH; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; INFECTION; LEUKOPENIA; LIVER TOXICITY; LYMPHOCYTOPENIA; MALE; METASTASIS; MOOD DISORDER; MUSCLE WEAKNESS; NAUSEA; PAIN; PHASE 2 CLINICAL TRIAL; POLYURIA; PRIORITY JOURNAL; PROSTATE CARCINOMA; RECTUM HEMORRHAGE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TINNITUS; TREATMENT FAILURE; TREATMENT OUTCOME; URINE INCONTINENCE; VERTIGO; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 0038353581     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(03)00145-6     Document Type: Article

References (22)

1. Basaria S., Lieb J., Tang A.M., et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol. 56:2002;779-786.
2. Berruti A., Dogliotti L., Terrone C., et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 167:2002;2361-2367.
3. Ross R.W., Small E.J. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol. 167:2002;1952-1956.
4. Grossfeld G.D., Chaudhary U.B., Reese D.M., et al. Intermittent androgen deprivation update of cycling characteristics in patients without clinically apparent metastatic prostate cancer . Urology. 58:2001;240-245.
5. Kolvenbag G.J., Iversen P., Newling D.W. Antiandrogen monotherapy a new form of treatment for patients with prostate cancer . Urology. 58:2001;16-23.
6. Bales GT, and Chodak GW: A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology 47: 38-43, discussion 48-53, 1996.
7. Iversen P., Tyrrell C.J., Kaisary A.V., et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer 6.3 years of followup . J Urol. 164:2000;1579-1582.
8. Boccardo F., Rubagotti A., Barichello M., et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients results of an Italian Prostate Cancer Project study . J Clin Oncol. 17:1999;2027-2038.
9. Chang A., Yeap B., Davis T., et al. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma flutamide versus diethylstilbestrol . J Clin Oncol. 14:1996;2250-2257.
10. Presti J.C. Jr, Fair W.R., Andriole G., et al. Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J Urol. 148:1992;1201-1204.
11. Brufsky A., Fontaine-Rothe P., Berlane K., et al. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology. 49:1997;913-920.
12. Fleshner N.E., Fair W.R. Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma. Br J Urol. 78:1996;907-910.
13. Fleshner N.E., Trachtenberg J. Combination finasteride and flutamide in advanced carcinoma of the prostate effective therapy with minimal side effects . J Urol. 154:1995;1642-1646.
14. Ornstein D.K., Rao G.S., Johnson B., et al. Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology. 48:1996;901-905.
15. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
16. Collett D. Modelling Survival Data in Medical Research. 1994;Chapman and Hall, London.
17. Kelly W.K. Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer. Eur Urol. 34:(suppl 3):1998;18-23.
18. Culig Z., Klocker H., Bartsch G., et al. Androgen receptor mutations in carcinoma of the prostate significance for endocrine therapy . Am J Pharmacogenom. 1:2001;241-249.
19. Kasimis B., Wilding G., Kreis W., et al. Survival of patients who had salvage castration after failure on bicalutamide monotherapy for stage (D2) prostate cancer. Cancer Invest. 18:2000;602-608.
20. Tan A., Tuckey J., Rice M. Orchidectomy following failure of antiandrogen monotherapy in patients with metastatic prostate cancer. Eur Urol. 40:2001;130-134.
21. Ornstein D.K., Smith D.S., Andriole G.L. Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed. Urology. 52:1998;1094-1097.
22. Tyrrell C.J., Kaisary A.V., Iversen P., et al. A randomised comparison of "Casodex" (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol. 33:1998;447-456.